Jenburkt Pharma launches FDC- Nervijen D3

Approved by Drug Controller General of India (DCGI), the FDC of Nervijen D3 may help manage symptoms of lower back pain, cervical spondylitis, sciatica, radiculopathy, prolapsed intervertebral disk (PIVD), diabetic peripheral neuropathy, pre-diabetes, metabolic syndrome, cardiovascular disease, alcoholic neuropathy, Vit B12, and Vit D3 deficiency.

"Vitamin D3 and B12 deficiency is a silent epidemic in India with almost 75% percent of the population showing alarming levels of deficiency. It's a known fact that nutritional deficiency has a great influence on nerve repair and worsens neuropathy and it is to address this very need that we have now launched Nervijen D3 tablets the fixed dose combination of Methylcobalamin with Vitamin D3" said Mr Rahul Pimpale, Group Product Manager, Jenburkt Pharmaceuticals Ltd.

"Nervijen D3 will provide a strong therapeutic armamentarium to physicians, neurologists and orthopedicans, in their efforts to protect, repair and restore nerve functions in their patients. The tablets have been launched in small size for better patient compliance." added Mrs Pradnya Pant, Sr Product Manager, Jenburkt Pharmaceuticals Ltd.

Jenburkt Pharmaceuticals Ltd. is a public listed company established in 1985, and is a deeply trusted professionally run company. Jenburkt manufactures pharmaceutical formulations in India and markets them domestically and internationally as well across 13 countries. It is well known for brands like Powergesic and Nervijen.

Disclaimer: This post has been published under MD Brand Connect Initiative and is sponsored by Jenburkt Pharmaceuticals Ltd.